Foster Dykema Cabot & Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.19 Trillion
- Q3 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 59,770 shares of VRTX stock, worth $24.4 Million. This represents 2.33% of its overall portfolio holdings.
Number of Shares
59,770
Previous 59,975
0.34%
Holding current value
$24.4 Million
Previous $28.1 Billion
1.12%
% of portfolio
2.33%
Previous 2.51%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.9 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.45 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.82 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.67 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $105B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...